UNSPSC 51182055: Nandrolone cyclohexanecarboxylate

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C25H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45FAH33FMM, chemically known as estr-4-en-3-one, 17-((cyclohexylcarbonyl)oxy)-, (17.beta.)-, but more generally known as nandrolone cyclohexanecarboxylate, which bears US NIH Compound Identifier 86744. European Medicines Agency schedules nandrolone cyclohexanecarboxylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09148MIG.

Most nations, for tariff purposes, schedule nandrolone cyclohexanecarboxylate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)C4CCCCC4)CCC5=CC(=O)CC[C@H]35.

UNSPSC 51182055 Nandrolone cyclohexanecarboxylate is a Commodity code tracking the procurement of this specific anabolic steroid pharmaceutical product by state and local government healthcare systems. Recent activity shows that state and local jurisdictions procure nandrolone cyclohexanecarboxylate as part of broader generic and branded pharmaceutical supply agreements established through cooperative purchasing vehicles, with distribution channeled through authorized pharmaceutical wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body for recent solicitations under this code, establishing multi-state purchasing agreements that serve participating state health agencies, correctional facilities, and local government healthcare providers across multiple jurisdictions including Oregon.

The geographic scope of recent procurement activity centers on the upper Midwest and Pacific Northwest, with Minnesota as the administrative hub for MMCAP and Oregon as a named participating jurisdiction. The Minnesota Department of Administration issued an RFP in January 2026 (Solicitation S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with responses due March 26, 2026. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), maintain cGMP certification and Drug Supply Chain Security Act compliance, and accept pricing structures including fixed price, net price formats, or WAC-minus arrangements. The contract term runs two years for new vendors with optional extensions, effective July 1, 2026, with MMCAP reserving the right to make sole, dual, or multi-awards based on therapeutic need and product availability.